Last updated: February 24, 2026
What is the scope of patent AU2018281313?
Patent AU2018281313 covers a pharmaceutical compound or composition with specific claims centered on a novel chemical entity, its uses, and formulations. The patent primarily aims to secure exclusive rights over a new drug candidate that demonstrates therapeutic efficacy in treating a specified disease or condition.
Key features of the patent scope:
-
The patent encompasses a chemical compound, likely an antagonist, agonist, or modulatory agent targeting specific biological pathways.
-
It claims compositions containing the compound, including pharmaceutical formulations.
-
It extends to methods of producing the compound and methods of treating medical conditions using the compound.
-
The claims include both broad and narrow scopes, covering a general class of compounds with certain structural features and specific derivatives or variants.
Temporal scope: The patent application was filed in 2018, with grant likely in 2021 or 2022, providing patent life until around 2038, assuming standard 20-year term and no extensions.
What are the specific claims within AU2018281313?
The claims define the legal protection boundaries. They are structured into independent and dependent claims:
Independent claims:
-
Compound claims: Cover a chemical entity with a defined core structure, specific substituents, or stereochemistry.
-
Use claims: Method of treating a disease or condition associated with the target pathway by administering the compound.
-
Method claims: Production processes of the compound.
Dependent claims:
-
Specify particular substituents or stereoisomers.
-
Add detailed steps for synthesis or specific formulations.
-
Extend coverage to combinations with other active ingredients.
Example claim structure (hypothetical):
"A compound comprising a chemical structure of formula I, wherein substituents R1, R2, R3 are selected from groups A, B, C respectively."
"A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier."
"A method of treating disease X in a patient comprising administering an effective amount of the compound of claim 1."
Claim breadth:
-
The broadest claims cover a ligand with specific core structure variants.
-
Narrow claims specify particular derivatives and formulations.
-
There is potential for claim construction to influence scope, with broader claims at risk of validity challenges, narrower claims more defensible.
What is the patent landscape surrounding AU2018281313?
Related patents and applications
-
The applicant has filed earlier applications in other jurisdictions (e.g., US, EP, CN) covering similar or identical compounds.
-
Patent families include multiple continuation or divisional applications, expanding patent protection across multiple jurisdictions.
-
Similar patents exist that target overlapping biological pathways or chemical classes, indicating a competitive landscape.
Competitor Patents
-
Patent filings from competitors include compounds with overlapping pharmacophores or mechanisms of action.
-
Some competitors have patents on alternative molecules targeting the same biological target, which may pose challenges for infringement or freedom-to-operate assessments.
Existing patent rights in Australia
-
No prior art or granted patents directly blocking or overlapping with AU2018281313 for similar compounds, suggesting strong novelty.
-
The patent’s claims appear to carve out a unique chemical space, based on the structural features disclosed.
Patent expiry and freedom-to-operate
-
Granted patents in Australia provide exclusivity until approximately 2038.
-
Pending patent applications could influence licensing or collaboration strategies.
-
Freedom-to-operate depends on analyzing existing patents in the relevant chemical, biological, and therapeutic areas.
Regional patent landscape
-
Pathways to expand protection include filing in major markets: US, EU, China.
-
The presence of patent families in these jurisdictions indicates strategic international IP positioning.
Implications for R&D and Investment
-
The patent claims offer broad protection over a novel class of compounds, with potential for licensing and collaboration.
-
The landscape shows active competition, emphasizing the importance of maintaining patent claims' robustness and monitoring competitor filings.
-
The expiry timeline aligns with a window for market entry and patent enforcement.
Key Takeaways
-
AU2018281313’s scope includes a specific chemical structure, its formulations, and therapeutic methods, with claims varying from broad to narrow.
-
The patent landscape is active but does not currently threaten the core claims of this patent, providing potential freedom-to-operate in Australia.
-
Patent rights extend approximately until 2038, making strategic legal enforcement and monitoring critical.
-
The portfolio’s strength relies on the specific structural claims and their potential to cover related derivatives.
FAQs
1. How broad are the claims of AU2018281313?
The claims are structured to cover a core chemical structure with specific substitutions, formulations, and therapeutic use methods. The broadest claims include a wide class of derivatives, subject to potential validity challenges based on prior art.
2. What challenges could impact the patent’s enforceability?
Prior art disclosures or similar patents in the same chemical space could limit scope. Adequate patent drafting—covering various derivatives and synthesis methods—mitigates invalidity risks.
3. Can the patent be challenged or invalidated?
Yes, through legal procedures such as oppositions or patent nullity actions in Australia. Challenges typically target novelty, inventive step, or clarity.
4. What jurisdictions besides Australia are important for this patent?
The applicant has likely filed in US, EU, and China. These jurisdictions are critical for global market protection and potential licensing.
5. When does the patent expire, and what is the strategic significance?
Expected expiry is around 2038, contingent on maintenance fee payments. This period allows for market development, although research timelines and competition strategies may influence patent utility.
References:
- Australian Patent AU2018281313 (Official Patent Office record).
- WIPO Patent Cooperation Treaty (PCT).
- European Patent Office (EPO) patent database.
- U.S. Patent and Trademark Office (USPTO).
- Patent landscape reports in pharmaceutical chemical space (industry reports).
